Autoimmune Diseases  >>  Privigen (human immune globulin intravenous 10%)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Privigen (human immune globulin intravenous 10%) / CSL Behring
NCT01390649 / 2011-000263-27: A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)

Completed
4
57
Europe, RoW
IgPro10, Privigen
CSL Behring
Immune Thrombocytopenic Purpura
09/14
09/14

Download Options